BMY Q2 2022 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q2 2022 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.9B+1.6% YoY

Gross Profit

$6.8B57.1% margin

Operating Income

$2.7B22.6% margin

Net Income

$1.4B12.0% margin

EPS (Diluted)

$0.66

QoQ Revenue Growth

+2.1%

Cash Flow

Operating Cash Flow

$2.3B

Free Cash Flow

$2.0B

Stock-Based Comp.

$116M

Balance Sheet

Total Assets

$100.4B

Total Liabilities

$67.7B

Stockholders' Equity

$32.6B

Cash & Equivalents

$10.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.9B	$11.7B	+1.6%
Gross Profit	$6.8B	$6.7B	+1.2%
Operating Income	$2.7B	$1.6B	+72.6%
Net Income	$1.4B	$1.1B	+34.7%

Revenue Segments

Eliquis

$3.2B28%

Revlimid

$2.5B21%

Opdivo

$2.1B18%

Pomalyst/Imnovid

$908M8%

Orencia

$876M7%

Sprycel

$544M5%

Yervoy

$525M4%

Mature Products And All Other

$435M4%

Abraxane

$241M2%

Reblozyl

$172M1%

Abecma

$89M1%

Zeposia

$66M1%

Opdualag

$58M0%

Breyanzi

$39M0%

Camzyos

$3M0%

Geographic Segments

UNITED STATES

$8.3B70%

Rest Of World

$3.4B29%

Other Region

$192M2%